Nasiri Mohammad J, Haeili Mehri, Ghazi Mona, Goudarzi Hossein, Pormohammad Ali, Imani Fooladi Abbas A, Feizabadi Mohammad M
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical SciencesTehran, Iran.
Department of Biology, Faculty of Natural Sciences, University of TabrizTabriz, Iran.
Front Microbiol. 2017 Apr 25;8:681. doi: 10.3389/fmicb.2017.00681. eCollection 2017.
Infectious diseases caused by clinically important Mycobacteria continue to be an important public health problem worldwide primarily due to emergence of drug resistance crisis. In recent years, the control of tuberculosis (TB), the disease caused by (MTB), is hampered by the emergence of multidrug resistance (MDR), defined as resistance to at least isoniazid (INH) and rifampicin (RIF), two key drugs in the treatment of the disease. Despite the availability of curative anti-TB therapy, inappropriate and inadequate treatment has allowed MTB to acquire resistance to the most important anti-TB drugs. Likewise, for most mycobacteria other than MTB, the outcome of drug treatment is poor and is likely related to the high levels of antibiotic resistance. Thus, a better knowledge of the underlying mechanisms of drug resistance in mycobacteria could aid not only to select the best therapeutic options but also to develop novel drugs that can overwhelm the existing resistance mechanisms. In this article, we review the distinctive mechanisms of antibiotic resistance in mycobacteria.
由具有临床重要性的分枝杆菌引起的传染病仍然是全球重要的公共卫生问题,主要原因是耐药危机的出现。近年来,由结核分枝杆菌(MTB)引起的结核病(TB)的控制受到多重耐药(MDR)出现的阻碍,多重耐药被定义为对治疗该疾病的两种关键药物——至少异烟肼(INH)和利福平(RIF)耐药。尽管有治愈性抗结核疗法,但不适当和不充分的治疗使MTB对最重要的抗结核药物产生了耐药性。同样,对于除MTB以外的大多数分枝杆菌,药物治疗效果不佳,这可能与高水平的抗生素耐药性有关。因此,更好地了解分枝杆菌耐药的潜在机制不仅有助于选择最佳治疗方案,还有助于开发能够克服现有耐药机制的新型药物。在本文中,我们综述了分枝杆菌抗生素耐药的独特机制。